RCUS — Arcus Biosciences Balance Sheet
0.000.00%
Last trade - 00:00
- $1.64bn
- $672.12m
- $117.00m
- 53
- 14
- 36
- 26
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 188 | 729 | 499 | 1,009 | 759 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.132 | 1.7 | 747 | 39 | 42 |
Prepaid Expenses | |||||
Total Current Assets | 193 | 736 | 1,262 | 1,067 | 831 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 9.33 | 23.6 | 137 | 135 | 143 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 203 | 772 | 1,592 | 1,345 | 1,095 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 22.7 | 122 | 166 | 193 | 184 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 39.3 | 270 | 750 | 688 | 633 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 164 | 502 | 841 | 657 | 462 |
Total Liabilities & Shareholders' Equity | 203 | 772 | 1,592 | 1,345 | 1,095 |
Total Common Shares Outstanding |